Filing Details

Accession Number:
0001144204-16-089880
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-23 17:27:02
Reporting Period:
2016-03-23
Filing Date:
2016-03-23
Accepted Time:
2016-03-23 17:27:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1430306 Tonix Pharmaceuticals Holding Corp. TNXP Pharmaceutical Preparations (2834) 261434750
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1563420 Seth Lederman C/O Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 306
New York NY 10022
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Acquisiton 2016-03-23 8,000 $2.44 80,815 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.001 Par Value 6,000 Indirect By spouse
Common Stock, $0.001 Par Value 29,167 Indirect By Leder Laboratories, Inc.
Common Stock, $0.001 Par Value 29,167 Indirect By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 Par Value 184,628 Indirect By Lederman & Co., LLC
Common Stock, $0.001 Par Value 32,457 Indirect By L&L Technologies, LLC
Common Stock, $0.001 Par Value 58,972 Indirect By Targent Pharmaceuticals, LLC
Footnotes
  1. The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $2.442145. The range of purchase prices on the transaction date was $2.40 to $2.48 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
  2. Reporting person may be deemed to be a control person of this entity.